Application of CRISPR/Cas9 technology in sepsis research. (10th February 2020)

• Record Type: Journal Article
• Authors: Wu, Miao; Hu, Niandan; Du, Xianjin; Wei, Jie
• Is Part Of: Briefings in functional genomics. Volume 19:Number 3(2020)
• Page Start: 229
• Page End: 234
• Publication Date: 2020-02-10
• Subjects: CRISPR/Cas9 -- sepsis -- genome editing; Genomics -- Methodology -- Periodicals; Genomics -- Technological innovations -- Periodicals; 572.86072
• DOI: 10.1093/bfgp/elz040
• Languages: English
• ISSNs: 2041-2649

Abstract

Abstract: CRISPR/Cas9, as a new genome-editing tool, offers new approaches to understand and treat diseases, which is being rapidly applied in various areas of biomedical research including sepsis field. The type II prokaryotic CRISPR/Cas system uses a single-guide RNA (sgRNA) to target the Cas9 nuclease to a specific genomic sequence, which is introduced into disease models for functional characterization and for testing of therapeutic strategies. This incredibly precise technology can be used for therapeutic research of gene-related diseases and to program any sequence in a target cell. Most importantly, the multifunctional capacity of this technology allows simultaneous editing of several genes. In this review, we focus on the basic principles, advantages and limitations of CRISPR/Cas9 and the use of the CRISPR/Cas9 system as a powerful tool in sepsis research and as a new strategy for the treatment of sepsis.